Logo image of DHB.CA

DELIVRA HEALTH BRANDS INC (DHB.CA) Stock Fundamental Analysis

TSX-V:DHB - TSX Venture Exchange - CA24703H2019 - Common Stock - Currency: CAD

0.205  0 (0%)

Fundamental Rating

3

Overall DHB gets a fundamental rating of 3 out of 10. We evaluated DHB against 35 industry peers in the Pharmaceuticals industry. The financial health of DHB is average, but there are quite some concerns on its profitability. DHB is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

DHB had negative earnings in the past year.
DHB had a negative operating cash flow in the past year.
In the past 5 years DHB reported 4 times negative net income.
In the past 5 years DHB reported 4 times negative operating cash flow.
DHB.CA Yearly Net Income VS EBIT VS OCF VS FCFDHB.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

The Return On Assets of DHB (-1.56%) is comparable to the rest of the industry.
DHB's Return On Equity of -3.18% is fine compared to the rest of the industry. DHB outperforms 62.86% of its industry peers.
Industry RankSector Rank
ROA -1.56%
ROE -3.18%
ROIC N/A
ROA(3y)-17.82%
ROA(5y)-68.21%
ROE(3y)-64.91%
ROE(5y)-143.71%
ROIC(3y)N/A
ROIC(5y)N/A
DHB.CA Yearly ROA, ROE, ROICDHB.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

1.3 Margins

DHB has a better Gross Margin (50.49%) than 80.00% of its industry peers.
In the last couple of years the Gross Margin of DHB has grown nicely.
DHB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 50.49%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.66%
GM growth 5Y9.71%
DHB.CA Yearly Profit, Operating, Gross MarginsDHB.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

4

2. Health

2.1 Basic Checks

DHB does not have a ROIC to compare to the WACC, probably because it is not profitable.
DHB has more shares outstanding than it did 1 year ago.
The number of shares outstanding for DHB has been increased compared to 5 years ago.
DHB has a worse debt/assets ratio than last year.
DHB.CA Yearly Shares OutstandingDHB.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
DHB.CA Yearly Total Debt VS Total AssetsDHB.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

DHB has an Altman-Z score of -21.00. This is a bad value and indicates that DHB is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -21.00, DHB is doing worse than 91.43% of the companies in the same industry.
DHB has a Debt/Equity ratio of 0.47. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of DHB (0.47) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF N/A
Altman-Z -21
ROIC/WACCN/A
WACC7.76%
DHB.CA Yearly LT Debt VS Equity VS FCFDHB.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M 100M

2.3 Liquidity

A Current Ratio of 3.43 indicates that DHB has no problem at all paying its short term obligations.
DHB has a better Current ratio (3.43) than 88.57% of its industry peers.
A Quick Ratio of 2.69 indicates that DHB has no problem at all paying its short term obligations.
DHB's Quick ratio of 2.69 is amongst the best of the industry. DHB outperforms 88.57% of its industry peers.
Industry RankSector Rank
Current Ratio 3.43
Quick Ratio 2.69
DHB.CA Yearly Current Assets VS Current LiabilitesDHB.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

DHB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 82.69%, which is quite impressive.
Looking at the last year, DHB shows a small growth in Revenue. The Revenue has grown by 4.04% in the last year.
Measured over the past years, DHB shows a quite strong growth in Revenue. The Revenue has been growing by 15.66% on average per year.
EPS 1Y (TTM)82.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50%
Revenue 1Y (TTM)4.04%
Revenue growth 3Y15.85%
Revenue growth 5Y15.66%
Sales Q2Q%0.78%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
DHB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.12% yearly.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year4.45%
Revenue Next 2Y9.12%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
DHB.CA Yearly Revenue VS EstimatesDHB.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M
DHB.CA Yearly EPS VS EstimatesDHB.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2025 2026 -0.2 -0.4 -0.6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

DHB is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DHB.CA Price Earnings VS Forward Price EarningsDHB.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DHB.CA Per share dataDHB.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 0.2 0.3 0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

DHB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DELIVRA HEALTH BRANDS INC

TSX-V:DHB (8/8/2025, 7:00:00 PM)

0.205

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-21 2025-05-21
Earnings (Next)10-06 2025-10-06
Inst Owners1.86%
Inst Owner ChangeN/A
Ins Owners12.72%
Ins Owner ChangeN/A
Market Cap6.41M
Analysts84.44
Price Target0.73 (256.1%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-2.7%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-66.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.51
P/FCF N/A
P/OCF N/A
P/B 1.52
P/tB 1.63
EV/EBITDA N/A
EPS(TTM)0
EYN/A
EPS(NY)-0.01
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0.4
BVpS0.13
TBVpS0.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.56%
ROE -3.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 50.49%
FCFM N/A
ROA(3y)-17.82%
ROA(5y)-68.21%
ROE(3y)-64.91%
ROE(5y)-143.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.66%
GM growth 5Y9.71%
F-Score3
Asset Turnover1.46
Health
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.43
Quick Ratio 2.69
Altman-Z -21
F-Score3
WACC7.76%
ROIC/WACCN/A
Cap/Depr(3y)1.34%
Cap/Depr(5y)42.2%
Cap/Sales(3y)0.22%
Cap/Sales(5y)16.46%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)82.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.04%
Revenue growth 3Y15.85%
Revenue growth 5Y15.66%
Sales Q2Q%0.78%
Revenue Next Year4.45%
Revenue Next 2Y9.12%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-26216.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year712.26%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y66.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y66.25%
OCF growth 3YN/A
OCF growth 5YN/A